Literature DB >> 14664755

Central nervous system toxicity from cancer treatment.

Terri Armstrong1, Mark R Gilbert.   

Abstract

Neurologic complications of cancer therapy are an increasingly important concern in patient management. Improvements in systemic therapies and increasing use of local treatments to target such specific tumor sites as brain or leptomeningeal metastases have resulted in increased incidence of treatment toxicity in the central nervous system (CNS). Recognition of specific treatment-related toxicities, and more importantly, differentiation of treatment toxicity from reversible causes of neurologic dysfunction, are critical. This article reviews the evaluation and treatment of major CNS toxicities related to cancer treatment and conditions that present with similar signs and symptoms. The three most common of these, alterations in cognition and consciousness, seizures, and cerebellar dysfunction, are discussed. Prompt recognition of these problems and their causes will have an impact on patient care in all areas of oncology.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14664755     DOI: 10.1007/s11912-996-0004-x

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  59 in total

1.  Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma.

Authors:  Tim A Ahles; Andrew J Saykin; Charlotte T Furstenberg; Bernard Cole; Leila A Mott; Karen Skalla; Marie B Whedon; Sarah Bivens; Tara Mitchell; E Robert Greenberg; Peter M Silberfarb
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

2.  Dementia following treatment of brain tumors with radiotherapy administered alone or in combination with nitrosourea-based chemotherapy: a clinical and pathological study.

Authors:  M C Vigliani; C Duyckaerts; J J Hauw; M Poisson; H Magdelenat; J Y Delattre
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

3.  ACUTE CEREBELLAR SYNDROME SECONDARY TO 5-FLUOROURACIL THERAPY.

Authors:  J L RIEHL; W J BROWN
Journal:  Neurology       Date:  1964-10       Impact factor: 9.910

Review 4.  Neurological complications of radiotherapy and chemotherapy.

Authors:  F Keime-Guibert; M Napolitano; J Y Delattre
Journal:  J Neurol       Date:  1998-11       Impact factor: 4.849

5.  Cognitive dysfunction associated with cancer and cancer therapy.

Authors:  C M Bender
Journal:  Medsurg Nurs       Date:  1995-10

6.  Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.

Authors:  G M Kiebert; D Curran; N K Aaronson; M Bolla; J Menten; E H Rutten; E Nordman; M E Silvestre; M Pierart; A B Karim
Journal:  Eur J Cancer       Date:  1998-11       Impact factor: 9.162

7.  The neurotoxicity of high-dose cytosine arabinoside is age-related.

Authors:  D Gottlieb; K Bradstock; J Koutts; T Robertson; C Lee; P Castaldi
Journal:  Cancer       Date:  1987-10-01       Impact factor: 6.860

8.  Effects of chemotherapy on the central nervous system. A study of parenteral methotrexate in long-term survivors of leukemia and lymphoma in childhood.

Authors:  A T Meadows; A E Evans
Journal:  Cancer       Date:  1976-02       Impact factor: 6.860

9.  Lorazepam for seizure prophylaxis during high-dose busulfan administration.

Authors:  K W Chan; C A Mullen; L L Worth; M Choroszy; S Koontz; H Tran; J Slopis
Journal:  Bone Marrow Transplant       Date:  2002-06       Impact factor: 5.483

Review 10.  Histopathology of CNS leukemia and complications of therapy.

Authors:  R A Price
Journal:  Am J Pediatr Hematol Oncol       Date:  1979
View more
  1 in total

Review 1.  Reducing the toxicity of cancer therapy: recognizing needs, taking action.

Authors:  Charles S Cleeland; Jeff D Allen; Samantha A Roberts; Joanna M Brell; Sergio A Giralt; Aarif Y Khakoo; Rebecca A Kirch; Virginia E Kwitkowski; Zhongxing Liao; Jamey Skillings
Journal:  Nat Rev Clin Oncol       Date:  2012-07-03       Impact factor: 66.675

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.